3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Breast Neoplasms
5
Recurrence
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Interventions
Gemcitabine
5
Cisplatin
4
enfortumab vedotin
2
Ramucirumab
2
Platinum
2
Docetaxel
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
rucaparib
1
pembrolizumab
1
eribulin
1
enzalutamide
1
dehydroftorafur
1
carotuximab
1
avelumab
1
atezolizumab
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiation
1
Paclitaxel
1
N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
1
Mitozytrex
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Interleukin-7
1
Immunoglobulin G
1
Icrucumab
1
IMC-18F1
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ureteral Neoplasms
×
rucaparib
×
Clear all
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts